Drug Discovery

Sygnature’s integrated drug discovery team offers a dynamic blend of new talent and pharmaceutical industry experience recruited from around the world, with more than 85% of our scientists holding PhDs. Mixed discipline laboratories facilitate clear communication, problem-solving and a rapid response to the changing needs of each of our customers’ research projects.

Our experienced drug hunters possess all the professional skills and know-how required to undertake your most demanding drug development and discovery programs and drive them from target validation, through hit identificationhit-to-lead and lead optimisation to development candidate.

Drug Discovery and Drug Development Process

We can develop a tailored drug development process that delivers robust data – for even the most complex projects – spanning a broad range of biophysical, biochemical, cellular and live cell imaging platforms as well as translational assays.

We offer a range of hit finding approaches, including fragment-based screens, medium-throughput screening, high-throughput screening and complementary in silico approaches.

During hit-to-lead projects our high-throughput chemistry capability enables the rapid design and synthesis of novel hit expansion libraries. Subsequent refinement using computational techniques and medicinal chemistry know-how, enables our scientific teams to generate high quality leads ready for further optimisation.

We incorporate early ADMET profiling, PK/PD correlations, and human dose prediction. As a consequence, Sygnature has delivered 34 pre-clinical candidates to clients; 17 of which have already progressed to healthy volunteer and patient-based trials.

The Drug Discovery Journey

Target Identification

Target Validation


Lead Optimisation

Candidate Nomination


Our involvement in the drug discovery process

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…